ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
- This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
- If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
- Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
- - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.